Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.22 USD
-0.02 (-1.61%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $1.28 +0.06 (4.92%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ACRS 1.22 -0.02(-1.61%)
Will ACRS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACRS
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
ACRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
Other News for ACRS
Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), Celcuity (CELC) and Intuitive Surgical (ISRG)
H.C. Wainwright Keeps Their Hold Rating on Aclaris Therapeutics (ACRS)
Aclaris Therapeutics Announces Sale of OLUMIANT? Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Aclaris Therapeutics Secures Deal with OMERS for OLUMIANT Royalties